Pactimibe is primarily investigated for its potential application in the management of cholesterol levels. It functions as an ACAT (Acyl-CoA: Cholesterol Acyltransferase) inhibitor, which plays a role in cholesterol absorption and esterification in the intestines and liver. By inhibiting this enzyme, Pactimibe aims to reduce the accumulation of cholesterol esters, thereby potentially lowering overall cholesterol levels in the body. This mechanism makes it a candidate for the treatment of hypercholesterolemia and related cardiovascular conditions. However, its development and clinical use have faced challenges due to mixed results in efficacy and safety studies, limiting its widespread application in therapeutic settings.